Table 3.

Effect of O-2093 and its four novel analogs on limb spasticity in mice with CREAE

Compound (dose)	n	Time from administration	Mean resistance to flexion force(N)±s.e.	P value
O–2247 (1 mg kg−1 i.v)	7	Baseline	0.237±0.020
		+10 min	0.249±0.027	NS
		+30 min	0.221±0.018	NS
		+60 min	0.249±0.031	NS
O–2248 (1 mg kg−1 i.v)	10	Baseline	0.258±0.034
		+10 min	0.252±0.031	NS
		+30 min	0.274±0.033	NS
		+60 min	0.255±0.019	NS
O–3246 (1 mg kg−1 i.v)	15	Baseline	0.250±0.018
		+10 min	0.240±0.017	NS
		+30 min	0.174±0.013	P<0.001
		+60 min	0.173±0.011	P<0.001
O–3262 (1 mg kg−1 i.v)	14	Baseline	0.208±0.011
		+10 min	0.153±0.007	P<0.001
		+30 min	0.140±0.008	P<0.001
		+60 min	0.153±0.009	P<0.001
O–2093 (1 mg kg−1 i.v)	13	Baseline	0.261±0.033
		+10 min	0.199±0.023	P=0.005
		+30 min	0.182±0.022	P<0.001
O–2093 (0.05 mg kg−1 i.v)	13	Baseline	0.172±0.048
		+10 min	0.117±0.045	P<0.001
		+30 min	0.111±0.037	P<0.001
		+60 min	0.095±0.033	P<0.001

Following the development of spasticity during the course of experimental allergic encephalomyelitis, the force required to bend individual spastic limbs to full flexion against a strain gauge was assessed. Compounds were injected at the dose indicated and recordings following drug administration were compared to baseline levels, using repeated measures Analysis of Variance. NS=non-significant (P>0.05).